Abstract
Opioid drugs are prescribed extensively for pain treatment but when used chronically they induce constipation that can progress to opioid-induced bowel dysfunction. Opioid drugs interact with three classes of opioid receptors: mu opioid receptors (MORs), delta opioid receptors (DOR), and kappa opioid receptors (KORs), but opioid drugs mostly target the MORs. Upon stimulation, opioid receptors couple to inhibitory Gi/Go proteins that activate or inhibit downstream effector proteins. MOR and DOR couple to inhibition of adenylate cyclase and voltage-gated Ca2+ channels and to activation of K+ channels resulting in reduced neuronal activity and neurotransmitter release. KORs couple to inhibition of Ca2+ channels and neurotransmitter release. In the gastrointestinal tract, opioid receptors are localized to enteric neurons, interstitial cells of Cajal, and immune cells. In humans, MOR, DOR, and KOR link to inhibition of acetylcholine release from enteric interneurons and motor neurons and purine/nitric oxide release from inhibitory motor neurons causing inhibition of propulsive motility patterns. MOR and DOR activation also results in inhibition of submucosal secretomotor neurons reducing active Cl− secretion and passive water movement into the colonic lumen. Together, these effects on motility and secretion account for the constipation caused by opioid receptor agonists. Tolerance develops to the analgesic effects of opioid receptor agonists but not to the constipating actions. This may be due to differences in trafficking and downstream signaling in enteric nerves in the colon compared to the small intestine and in neuronal pain pathways. Further studies of differential opioid receptor desensitization and tolerance in subsets of enteric neurons may identify new drug or other treatment strategies of opioid-induced bowel dysfunction.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alex G, Clerc N, Kunze WA, Furness JB (2002) Responses of myenteric S neurones to low frequency stimulation of their synaptic inputs. Neuroscience 110:361–373
Anselmi L, Jaramillo I, Palacios M, Huynh J, Sternini C (2013) Ligand-induced mu opioid receptor internalization in enteric neurons following chronic treatment with the opiate fentanyl. J Neurosci Res 91:854–860
Anselmi L, Huynh J, Duraffourd C, Jaramillo I, Vegezzi G, Saccani F, Boschetti E, Brecha NC, De Giorgio R, Sternini C (2015) Activation of mu opioid receptors modulates inflammation in acute experimental colitis. Neurogastroenterol Motil 27:509–523
Awouters F, Niemegeers CJ, Janssen PA (1983) Pharmacology of antidiarrheal drugs. Annu Rev Pharmacol Toxicol 23:279–301
Bader S, Durk T, Becker G (2013) Methylnaltrexone for the treatment of opioid-induced constipation. Expert Rev Gastroenterol Hepatol 7:13–26
Bagnol D, Mansour A, Akil H, Watson SJ (1997) Cellular localization and distribution of the cloned mu and kappa opioid receptors in rat gastrointestinal tract. Neuroscience 81:579–591
Bailey CP, Smith FL, Kelly E, Dewey WL, Henderson G (2006) How important is protein kinase C in mu-opioid receptor desensitization and morphine tolerance? Trends Pharmacol Sci 27:558–565
Banks MR, Farthing MJ, Robberecht P, Burleigh DE (2005) Antisecretory actions of a novel vasoactive intestinal polypeptide (VIP) antagonist in human and rat small intestine. Br J Pharmacol 144:994–1001
Bauer AJ, Sarr MG, Szurszewski JH (1991) Opioids inhibit neuromuscular transmission in circular muscle of human and baboon jejunum. Gastroenterology 101:970–976
Bishop-Freeman SC, Feaster MS, Beal J, Miller A, Hargrove RL, Brower JO, Winecker RE (2016) Loperamide-related deaths in North Carolina. J Anal Toxicol 40:677–686
Brookes SJ (2001) Classes of enteric nerve cells in the guinea-pig small intestine. Anat Rec 262:58–70
Bui K, She F, Zhou D, Butler K, Al-Huniti N, Sostek M (2016) The effect of quinidine, a strong P-glycoprotein inhibitor, on the pharmacokinetics and central nervous system distribution of naloxegol. J Clin Pharmacol 56:497–505
Chamouard P, Klein A, Martin E, Adloff M, Angel F (1993) Regulatory role of enteric kappa opioid receptors in human colonic motility. Life Sci 53:1149–1156
Chamouard P, Rohr S, Meyer C, Baumann R, Angel F (1994) Delta-opioid receptor agonists inhibit neuromuscular transmission in human colon. Eur J Pharmacol 262:33–39
Cherubini E, North RA (1985) Mu and kappa opioids inhibit transmitter release by different mechanisms. Proc Natl Acad Sci U S A 82:1860–1863
Cherubini E, Morita K, North RA (1985) Opioid inhibition of synaptic transmission in the guinea-pig myenteric plexus. Br J Pharmacol 85:805–817
Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J (2014) Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med 370:2387–2396
Christie MJ (2008) Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br J Pharmacol 154:384–396
Claing A, Laporte SA, Caron MG, Lefkowitz RJ (2002) Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins. Prog Neurobiol 66:61–79
Daniulaityte R, Carlson R, Falck R, Cameron D, Perera S, Chen L, Sheth A (2013) “I just wanted to tell you that loperamide WILL WORK”: a web-based study of extra-medical use of loperamide. Drug Alcohol Depend 130:241–244
Davis TP, Sanchez-Covarubias L, Tome ME (2014) P-glycoprotein trafficking as a therapeutic target to optimize CNS drug delivery. Adv Pharmacol 71:25–44
DeWire SM, Yamashita DS, Rominger DH, Liu G, Cowan CL, Graczyk TM, Chen XT, Pitis PM, Gotchev D, Yuan C, Koblish M, Lark MW, Violin JD (2013) A G protein-biased ligand at the mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther 344:708–717
Duraffourd C, Kumala E, Anselmi L, Brecha NC, Sternini C (2014) Opioid-Induced mitogen-activated protein kinase signaling in rat enteric neurons following chronic morphine treatment. PLoS One 9:e110230
Eggleston W, Clark KH, Marraffa JM (2017) Loperamide abuse associated with cardiac dysrhythmia and death. Ann Emerg Med 69:83–86
Fei G, Raehal K, Liu S, Qu MH, Sun X, Wang GD, Wang XY, Xia Y, Schmid CL, Bohn LM, Wood JD (2010) Lubiprostone reverses the inhibitory action of morphine on intestinal secretion in guinea pig and mouse. J Pharmacol Exp Ther 334:333–340
Finn AK, Whistler JL (2001) Endocytosis of the mu opioid receptor reduces tolerance and a cellular hallmark of opiate withdrawal. Neuron 32:829–839
Fujita W, Gomes I, Devi LA (2015) Heteromers of mu-delta opioid receptors: new pharmacology and novel therapeutic possibilities. Br J Pharmacol 172:375–387
Gade AR, Kang M, Khan F, Grider JR, Damaj MI, Dewey WL, Akbarali HI (2016) Enhanced sensitivity of alpha3beta4 nicotinic receptors in enteric neurons after long-term morphine: implication for opioid-induced constipation. J Pharmacol Exp Ther 357:520–528
Galligan JJ, Akbarali HI (2014) Molecular physiology of enteric opioid receptors. Am J Gastroenterol Suppl 2:17–21
Galligan JJ, LePard KJ, Schneider DA, Zhou X (2000) Multiple mechanisms of fast excitatory synaptic transmission in the enteric nervous system. J Auton Nerv Syst 81:97–103
Gomes I, Gupta A, Filipovska J, Szeto HH, Pintar JE, Devi LA (2004) A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc Natl Acad Sci U S A 101:5135–5139
Gray AC, Coupar IM, White PJ (2006) Comparison of opioid receptor distributions in the rat ileum. Life Sci 78:1610–1616
Grunkemeier DM, Cassara JE, Dalton CB, Drossman DA (2007) The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin Gastroenterol Hepatol 5:1126–1139, quiz 1121–1122
Heyman JS, Williams CL, Burks TF, Mosberg HI, Porreca F (1988) Dissociation of opioid antinociception and central gastrointestinal propulsion in the mouse: studies with naloxonazine. J Pharmacol Exp Ther 245:238–243
Ho A, Lievore A, Patierno S, Kohlmeier SE, Tonini M, Sternini C (2003) Neurochemically distinct classes of myenteric neurons express the μ-opioid receptor in the guinea pig ileum. J Comp Neurol 458:404–411
Hughes PA, Costello SP, Bryant RV, Andrews JM (2016) Opioidergic effects on enteric and sensory nerves in the lower GI tract: basic mechanisms and clinical implications. Am J Physiol Gastrointest Liver Physiol 311:G501–G513
Hwang SJ, Durnin L, Dwyer L, Rhee PL, Ward SM, Koh SD, Sanders KM, Mutafova-Yambolieva VN (2011) beta-nicotinamide adenine dinucleotide is an enteric inhibitory neurotransmitter in human and nonhuman primate colons. Gastroenterology 140:608–617, e606
Jin JG, Murthy KS, Grider JR, Makhlouf GM (1996) Stoichiometry of neurally induced VIP release, NO formation, and relaxation in rabbit and rat gastric muscle. Am J Physiol 271:G357–G369
Jordan BA, Devi LA (1999) G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399:697–700
Kang M, Maguma HT, Smith TH, Ross GR, Dewey WL, Akbarali HI (2012) The role of beta-arrestin2 in the mechanism of morphine tolerance in the mouse and guinea pig gastrointestinal tract. J Pharmacol Exp Ther 340:567–576
Kang J, Compton DR, Vaz RJ, Rampe D (2016) Proarrhythmic mechanisms of the common anti-diarrheal medication loperamide: revelations from the opioid abuse epidemic. Naunyn Schmiedebergs Arch Pharmacol 389:1133–1137
Kim HJ, Kim H, Jung MH, Kwon YK, Kim BJ (2016) Berberine induces pacemaker potential inhibition via cGMP-dependent ATP-sensitive K+ channels by stimulating mu/delta opioid receptors in cultured interstitial cells of Cajal from mouse small intestine. Mol Med Rep 14:3985–3991
Kopic S, Corradini S, Sidani S, Murek M, Vardanyan A, Foller M, Ritter M, Geibel JP (2010) Ethanol inhibits gastric acid secretion in rats through increased AMP-kinase activity. Cell Physiol Biochem 25:195–202
Lacy BE (2016) Emerging treatments in neurogastroenterology: eluxadoline – a new therapeutic option for diarrhea-predominant IBS. Neurogastroenterol Motil 28:26–35
Lay J, Carbone SE, DiCello JJ, Bunnett NW, Canals M, Poole DP (2016) Distribution and trafficking of the mu-opioid receptor in enteric neurons of the guinea pig. Am J Physiol Gastrointest Liver Physiol 311:G252–G266
Lembo AJ, Lacy BE, Zuckerman MJ, Schey R, Dove LS, Andrae DA, Davenport JM, McIntyre G, Lopez R, Turner L, Covington PS (2016) Eluxadoline for irritable bowel syndrome with diarrhea. N Engl J Med 374:242–253
Leppert W, Woron J (2016) The role of naloxegol in the management of opioid-induced bowel dysfunction. Ther Adv Gastroenterol 9:736–746
Liu JG, Anand KJ (2001) Protein kinases modulate the cellular adaptations associated with opioid tolerance and dependence. Brain Res Brain Res Rev 38:1–19
Madden JJ, Whaley WL, Ketelsen D (1998) Opiate binding sites in the cellular immune system: expression and regulation. J Neuroimmunol 83:57–62
Manglik A, Lin H, Aryal DK, McCorvy JD, Dengler D, Corder G, Levit A, Kling RC, Bernat V, Hubner H, Huang XP, Sassano MF, Giguere PM, Lober S, Da D, Scherrer G, Kobilka BK, Gmeiner P, Roth BL, Shoichet BK (2016) Structure-based discovery of opioid analgesics with reduced side effects. Nature 537:185–190
Martini L, Whistler JL (2007) The role of mu opioid receptor desensitization and endocytosis in morphine tolerance and dependence. Curr Opin Neurobiol 17:556–564
Mihara S, North RA (1986) Opioids increase potassium conductance in submucous neurones of guinea-pig caecum by activating delta-receptors. Br J Pharmacol 88:315–322
Minnis J, Patierno S, Kohlmeier SE, Brecha N, Tonini M, Sternini C (2003) Ligand-induced μ opioid receptor endocytosis and recycling in enteric neurons. Neuroscience 119:33–42
Mori T, Shibasaki Y, Matsumoto K, Shibasaki M, Hasegawa M, Wang E, Masukawa D, Yoshizawa K, Horie S, Suzuki T (2013) Mechanisms that underlie mu-opioid receptor agonist-induced constipation: differential involvement of mu-opioid receptor sites and responsible regions. J Pharmacol Exp Ther 347:91–99
Morita K, North RA (1982) Opiate activation of potassium conductance in myenteric neurons: inhibition by calcium ion. Brain Res 242:145–150
North RA, Williams JT, Surprenant A, Christie MJ (1987) Mu and delta receptors belong to a family of receptors that are coupled to potassium channels. Proc Natl Acad Sci U S A 84:5487–5491
Pan YX (2005) Diversity and complexity of the mu opioid receptor gene: alternative pre-mRNA splicing and promoters. DNA Cell Biol 24:736–750
Pasternak GW (2001) Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacol Sci 22:67–70
Patierno S, Anselmi L, Jaramillo I, Scott D, Garcia R, Sternini C (2011) Morphine induces mu opioid receptor endocytosis in guinea pig enteric neurons following prolonged receptor activation. Gastroenterology 140:618–626
Philippe D, Dubuquoy L, Groux H, Brun V, Chuoi-Mariot MT, Gaveriaux-Ruff C, Colombel JF, Kieffer BL, Desreumaux P (2003) Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation. J Clin Invest 111:1329–1338
Philippe D, Chakass D, Thuru X, Zerbib P, Tsicopoulos A, Geboes K, Bulois P, Breisse M, Vorng H, Gay J, Colombel JF, Desreumaux P, Chamaillard M (2006) Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation. Gut 55:815–823
Poole DP, Pelayo JC, Scherrer G, Evans CJ, Kieffer BL, Bunnett NW (2011) Localization and regulation of fluorescently labeled delta opioid receptor, expressed in enteric neurons of mice. Gastroenterology 141:982–991, e988
Poonyachoti S, Kulkarni-Narla A, Brown DR (2002) Chemical coding of neurons expressing ∂- and k-opioid receptor and type I vanilloind receptor immunoreactivities in the porcine ileum. Cell Tissue Res 307:23–33
Raehal KM, Schmid CL, Groer CE, Bohn LM (2011) Functional selectivity at the mu-opioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacol Rev 63:1001–1019
Ross GR, Gabra BH, Dewey WL, Akbarali HI (2008) Morphine tolerance in the mouse ileum and colon. J Pharmacol Exp Ther 327:561–572
Saccani F, Anselmi L, Jaramillo I, Bertoni S, Barocelli E, Sternini C (2012) Protective role of mu opioid receptor activation in intestinal inflammation induced by mesenteric ischemia/reperfusion in mice. J Neurosci Res 90:2146–2153
Shen KZ, Surprenant A (1991) Noradrenaline, somatostatin and opioids inhibit activity of single HVA/N-type calcium channels in excised neuronal membranes. Pflugers Arch 418:614–616
Smith TH, Grider JR, Dewey WL, Akbarali HI (2012) Morphine decreases enteric neuron excitability via inhibition of sodium channels. PLoS One 7:e45251
Stefano GB, Scharrer B, Smith EM, Hughes TK Jr, Magazine HI, Bilfinger TV, Hartman AR, Fricchione GL, Liu Y, Makman MH (1996) Opioid and opiate immunoregulatory processes. Crit Rev Immunol 16:109–144
Sternini C (2001) Receptors and transmission in the brain-gut axis: potential for novel therapies. III. μ opioid receptors in the enteric nervous system. Am J Physiol 281:G8–G15
Sternini C, Spann M, Anton B, Keith DE Jr, Bunnett NW, von Zastrow M, Evans C, Brecha NC (1996) Agonist-selective endocytosis of μ opioid receptor by neurons in vivo. Proc Natl Acad Sci U S A 93:9241–9246
Sternini C, Patierno S, Selmer IS, Kirchgessner A (2004) The opioid system in the gastrointestinal tract. Neurogastroenterol Motil 16(Suppl 2):3–16
Surprenant A, Shen KZ, North RA, Tatsumi H (1990) Inhibition of calcium currents by noradrenaline, somatostatin and opioids in guinea-pig submucosal neurones. J Physiol 431:585–608
Tatsumi H, Costa M, Schimerlik M, North RA (1990) Potassium conductance increased by noradrenaline, opioids, somatostatin, and G-proteins: whole-cell recording from guinea pig submucous neurons. J Neurosci 10:1675–1682
Vandenbossche J, Huisman M, Xu Y, Sanderson-Bongiovanni D, Soons P (2010) Loperamide and P-glycoprotein inhibition: assessment of the clinical relevance. J Pharm Pharmacol 62:401–412
Vaughn P, Solik MM, Bagga S, Padanilam BJ (2016) Electrocardiographic abnormalities, malignant ventricular arrhythmias, and cardiomyopathy associated with loperamide abuse. J Cardiovasc Electrophysiol 27:1230–1233
Violin JD, Lefkowitz RJ (2007) Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci 28:416–422
Wade PR, Palmer JM, McKenney S, Kenigs V, Chevalier K, Moore BA, Mabus JR, Saunders PR, Wallace NH, Schneider CR, Kimball ES, Breslin HJ, He W, Hornby PJ (2012) Modulation of gastrointestinal function by MuDelta, a mixed micro opioid receptor agonist/ micro opioid receptor antagonist. Br J Pharmacol 167:1111–1125
Webster LR, Brenner DM, Barrett AC, Paterson C, Bortey E, Forbes WP (2015) Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain. J Pain Res 8:771–780
Williams JT, Ingram SL, Henderson G, Chavkin C, von Zastrow M, Schulz S, Koch T, Evans CJ, Christie MJ (2013) Regulation of mu-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev 65:223–254
Zhou X, Brown E, Schneider D, Caraballo-Lopez Y, Galligan JJ (2002) Pharmacological properties of nicotinic acetylcholine receptors expressed by guinea pig small intestinal myenteric neurons. J Pharmacol Exp Ther 302:889–897
Acknowledgments
This work was supported by NIH DK094932 (JJG), NIH P30 DK41301, Imaging Core (CS).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing AG
About this chapter
Cite this chapter
Galligan, J.J., Sternini, C. (2016). Insights into the Role of Opioid Receptors in the GI Tract: Experimental Evidence and Therapeutic Relevance. In: Greenwood-Van Meerveld, B. (eds) Gastrointestinal Pharmacology . Handbook of Experimental Pharmacology, vol 239. Springer, Cham. https://doi.org/10.1007/164_2016_116
Download citation
DOI: https://doi.org/10.1007/164_2016_116
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-56359-6
Online ISBN: 978-3-319-56360-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)